Drugs / Biperiden

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) AKINETON 1959-09-08 fda.gov

Trials 6 · a red edge is where a trial was stopped

19581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT00495092 Jan 2005 → Dec 2009 cocaine dependence Hospital Universitari Vall d'Hebron Research Institute Completed No outcome recorded
Phase 34 trials
Phase 3 NCT04945213 Jan 2023 → Dec 2026 expected post-traumatic epilepsy, traumatic brain injury Hospital Sirio-Libanes Recruiting No outcome recorded
Phase 3 NCT01048138 Jan 2018 → Dec 2022 traumatic brain injury Federal University of São Paulo Terminated No outcome recorded
Phase 3 NCT02374567 Jan 2015 → Jun 2017 anxiety disorder, dementia, depressive disorder, schizophrenia +1 Hannover Medical School Terminated No outcome recorded
Phase 3 NCT01251393 May → Dec 2011 cocaine dependence Federal University of São Paulo Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00495183 Jan 2009 → Jul 2010 cocaine dependence Hospital Universitari Vall d'Hebron Research Institute Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02078336 Comparator Dec 2013 → Jul 2025 overdue Universitaire Ziekenhuizen KU Leuven Active not recruiting No outcome recorded

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Biperiden ClinicalTrials.gov intervention name — accepted as the source's own label NCT00495092
5

NCT00495183

NCT01251393

NCT02374567

NCT01048138

NCT04945213

Known as Akineton ClinicalTrials.gov intervention name — accepted as the source's own label NCT02078336
Known as Akineton ret ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Akinophyl ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Biperiden hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as BIPERIDEN HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Biperiden Lactate “Drug: Biperiden LactateNCT01048138
Known as Biperidene ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Biperideni hydrochloridum ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Biperideno ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Biperidenum ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as KL 373 ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as NSC-170950 ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as NSC-759145 ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as NSC-84989 ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Known as Tasmolin ChEMBL registry synonym — accepted as the source's own label CHEMBL1101
Action Inhibit “Biperiden is a cholinergic antagonist, acting in the muscarinic receptor” NCT01048138
1

“Muscarinic acetylcholine receptor M1 antagonist” CHEMBL1101

Modality Small molecule CHEMBL1101
Route Oral “Biperiden 2-4 mg/d p.o.” NCT00495092
Target CHRM1 “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL1101